BR0115847A - Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos - Google Patents

Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos

Info

Publication number: BR0115847A
Authority: BR; Brazil
Prior art keywords: compounds; specific compounds; adenosine receptor; receptor specific; patient
Prior art date: 2000-12-01

Application number

BR0115847-3A

Other languages

English (en)

Portuguese (pt)

Inventor

Arlindo L Castelhano

Bryan Mckibben

David J Witter

Original Assignee

Osi Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2001-11-30

Publication date

2004-02-25

2000-12-01 Priority claimed from US09/728,607 external-priority patent/US6664252B2/en

2000-12-01 Priority claimed from US09/728,616 external-priority patent/US7160890B2/en

2000-12-01 Priority claimed from US09/728,316 external-priority patent/US6680322B2/en

2001-11-30 Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

2004-02-25 Publication of BR0115847A publication Critical patent/BR0115847A/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 5
102000009346 Adenosine receptors Human genes 0.000 title abstract 3
108050000203 Adenosine receptors Proteins 0.000 title abstract 3
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
229960005305 adenosine Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR0115847-3A 2000-12-01 2001-11-30 Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos BR0115847A (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US09/728,607 US6664252B2 (en)	1999-12-02	2000-12-01	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,616 US7160890B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A3 receptor and uses thereof
US09/728,316 US6680322B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A1 receptors and uses thereof
PCT/US2001/045280 WO2002057267A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (1)

Publication Number	Publication Date
BR0115847A true BR0115847A (pt)	2004-02-25

Family

ID=27419112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0115847-3A BR0115847A (pt)	2000-12-01	2001-11-30	Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos

Country Status (20)

Country	Link
EP (1)	EP1347980A4 (cs)
JP (1)	JP4579497B2 (cs)
CN (1)	CN1263757C (cs)
AP (1)	AP1893A (cs)
AU (1)	AU2002248151B2 (cs)
BR (1)	BR0115847A (cs)
CA (1)	CA2430577A1 (cs)
CZ (1)	CZ20031831A3 (cs)
EA (1)	EA007254B1 (cs)
HU (1)	HUP0400692A3 (cs)
IL (1)	IL155962A0 (cs)
ME (1)	MEP35308A (cs)
MX (1)	MXPA03004717A (cs)
NO (1)	NO327207B1 (cs)
NZ (1)	NZ525885A (cs)
OA (1)	OA13295A (cs)
PL (1)	PL363245A1 (cs)
WO (1)	WO2002057267A1 (cs)
YU (1)	YU42703A (cs)
ZA (1)	ZA200303729B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5090531A (en) *	1990-01-10	1992-02-25	Lord Corporation	Electrophoretic fluid differential
IL139787A0 (en)	1998-06-02	2002-02-10	Osi Pharm Inc	PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) *	2001-10-04	2003-04-10	Merck Patent Gmbh	Pyrimidinderivate
DE60234118D1 (de) *	2001-11-30	2009-12-03	Osi Pharm Inc	Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
CA2469316A1 (en) *	2001-12-07	2003-06-19	Vertex Pharmaceuticals, Inc.	Pyrimidine-based compounds useful as gsk-3 inhibitors
US20030229067A1 (en)	2001-12-20	2003-12-11	Arlindo Castelhano	Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
BR0215202A (pt)	2001-12-20	2004-10-13	Osi Pharm Inc	Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
AU2003270701B2 (en) *	2002-10-31	2009-11-12	Amgen Inc.	Antiinflammation agents
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ATE464904T1 (de) *	2005-02-18	2010-05-15	Solvay Pharm Gmbh	Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
JP5606734B2 (ja)	2006-04-25	2014-10-15	アステックス、セラピューティックス、リミテッド	医薬化合物
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
BRPI0818533B8 (pt)	2007-10-11	2021-05-25	Astrazeneca Ab	composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
WO2009098715A2 (en)	2008-01-11	2009-08-13	Natco Pharma Limited	Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
WO2012131399A1 (en)	2011-04-01	2012-10-04	Astrazeneca Ab	Therapeutic treatment
PT2785349T (pt)	2011-11-30	2019-12-11	Astrazeneca Ab	Tratamento combinado de cancro
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
HK1202112A1 (en) *	2012-06-07	2015-09-18	霍夫曼-拉罗奇有限公司	Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2015004533A2 (en)	2013-06-21	2015-01-15	Zenith Epigenetics Corp.	Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en)	2013-06-21	2016-01-28	Zenith Epigenetics Corp	Novel bicyclic bromodomain inhibitors
AU2014298051B2 (en)	2013-07-31	2018-11-15	Zenith Epigenetics Ltd.	Novel quinazolinones as bromodomain inhibitors
WO2016087942A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Corp.	Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Corp.	Substituted pyridinones as bromodomain inhibitors
CN107207474B (zh)	2014-12-11	2021-05-07	恒翼生物医药科技(上海)有限公司	被取代的杂环作为溴结构域抑制剂
CA2966450A1 (en)	2014-12-17	2016-06-23	Olesya KHARENKO	Inhibitors of bromodomains
AU2016208906B2 (en) *	2015-01-20	2018-07-12	Wuxi Fortune Pharmaceutical Co., Ltd	JAK inhibitor
UA119701C2 (uk)	2015-04-29	2019-07-25	Вуксі Фортуне Фармасьютікал Ко., Лтд	Піримідинові сполуки як jak-інгібітори
DK3305788T3 (da)	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus-kinase-hæmmer
CN105771672B (zh) *	2016-04-18	2018-03-02	天津工业大学	一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
US11066413B2 (en) *	2017-03-07	2021-07-20	Guangzhou Maxinovel Pharmaceuticals Co., Ltd.	Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂
WO2019233994A1 (en) *	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (zh) *	2019-05-22	2021-08-31	北京大学深圳研究生院	5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) *	2019-07-02	2022-07-29	天津国际生物医药联合研究院	一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) *	2021-12-29	2022-02-25	苏州楚凯药业有限公司	一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2128544T3 (es) *	1992-12-17	1999-05-16	Pfizer	Pirrolopirimidinas como antagonistas del crf.
US5780450A (en) *	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
IL139787A0 (en) *	1998-06-02	2002-02-10	Osi Pharm Inc	PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
WO2001039777A1 (en) *	1999-12-02	2001-06-07	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
DE60234118D1 (de) *	2001-11-30	2009-12-03	Osi Pharm Inc	Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen

2001
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en not_active Ceased
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2430577A1 (en)	2002-07-25
JP2004517896A (ja)	2004-06-17
EP1347980A4 (en)	2005-02-09
CN1263757C (zh)	2006-07-12
IL155962A0 (en)	2003-12-23
OA13295A (en)	2007-04-13
WO2002057267A1 (en)	2002-07-25
AP2003002807A0 (en)	2003-06-30
AU2002248151B2 (en)	2008-02-21
MXPA03004717A (es)	2004-06-30
AP1893A (en)	2008-09-23
CZ20031831A3 (cs)	2004-05-12
ZA200303729B (en)	2004-05-14
NO20032482L (no)	2003-07-28
NZ525885A (en)	2005-01-28
YU42703A (sh)	2006-03-03
NO20032482D0 (no)	2003-06-02
MEP35308A (en)	2011-02-10
EA200300628A1 (ru)	2003-12-25
EP1347980A1 (en)	2003-10-01
HUP0400692A2 (hu)	2004-07-28
EA007254B1 (ru)	2006-08-25
CN1489590A (zh)	2004-04-14
JP4579497B2 (ja)	2010-11-10
HUP0400692A3 (en)	2007-09-28
NO327207B1 (no)	2009-05-11
PL363245A1 (en)	2004-11-15

Legal Events

Date	Code	Title	Description
2011-04-19	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2011-11-01	B09B	Patent application refused [chapter 9.2 patent gazette]
2012-08-21	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

Publication	Publication Date	Title
AP1893A (en)	2008-09-23	Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
BR0309544A (pt)	2005-02-01	Preparação farmacêutica contendo oxicodona e naloxona
WO2001039777A8 (en)	2001-11-08	Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
BR0012136A (pt)	2002-06-11	Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
AR023715A1 (es)	2002-09-04	Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
BR0213358A (pt)	2004-10-26	Uso de flibanserina
BR0112476A (pt)	2003-07-22	Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0011856A (pt)	2004-02-10	Agonistas de receptor a2a de n-pirazol
BR9910035A (pt)	2000-12-26	Derivados de guanidina
BR0309855A (pt)	2005-03-01	Pirazolpiridinas substituìdas com carbamato
BR9913932A (pt)	2001-10-16	Uso de análogos de glp-1 no tratamento de derrame
BR0108977A (pt)	2004-01-06	Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
BR0011854A (pt)	2002-06-11	Agonistas de receptores de a2a de c-pirazola
FI920026A0 (fi)	1992-01-03	Farmaceutisk komposition anvaendbar som avmagringsmedicin.
BR0115109A (pt)	2005-10-18	Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BRPI0007487B8 (pt)	2021-05-25	difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0014525A (pt)	2002-06-11	Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
PT777482E (pt)	2002-04-29	Composicao de combinacao para utilizacao em doencas imunologicas
AR052921A1 (es)	2007-04-11	Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
AR015493A1 (es)	2001-05-02	DERIVADOS CICLOHEXILOS , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA COMPOSICIoN uTIL PARA INHIBIR LA ACTIVIDAD IN VITRO DE NEURAMINIDASA Y PARA EL TRATAMIENTO O PROFILAXIS DE LA INFECCIoN DE INFLUENZA Y PARA TRATAIMIENTO, Y UN MÉTODO IN VITRO PARA INHIBIR LA ACTIVI
BR0111913A (pt)	2004-01-06	Análogos de gabapentina para distúrbios do sono
BR0011850A (pt)	2002-05-21	Agonistas de receptor a2a de propargil fenil éter
BR0009524A (pt)	2002-02-19	Uso de um composto, e, composição farmacêutica ou veterinaria
BR0010669A (pt)	2002-02-19	Método para o tratamento de fibrose usando um antagonista da subunidade alfa-4 da integrina
BR0316042A (pt)	2005-09-13	Kits que contêm compressa para o corpo e dispositivo térmico fixável de modo liberável